|Articles|June 1, 2010

Health Economic Perspectives in Fibromyalgia: Focus on Pregabalin
Volume 16
Issue 5

eAppendix

Download PDF: eAppendix

Articles in this issue

about 16 years ago

Article

Impact of a Prior Authorization for Pregabalin on Health Plan Drug Expenditures

about 16 years ago

Article

Pregabalin: An Alpha2-delta (a2-d) Ligand for the Management of Fibromyalgia

about 16 years ago

Article

Financial and Clinical Characteristics of Fibromyalgia: A Case-Control Comparison

about 16 years ago

Article

Initial Use of Pregabalin, Patterns of Pain-Related Pharmacotherapy, and Healthcare Resource Use Among Older Patients With Fibromyalgia

about 16 years ago

Article

Introduction

about 16 years ago

Article

Participating Faculty

about 16 years ago

Article

Patterns of Healthcare Utilization and Cost in Patients With Newly Diagnosed Fibromyalgia

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

eAppendix

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029

Fifth Death Confirmed in NYC Legionnaires' Outbreak

Obesity, Insulin Resistance, and the Silent Progression of MASH: A Hepatologist's Perspective

How Portable Oxygen Is Changing Home Respiratory Care: Doug Francis

Pirtobrutinib Plus Venetoclax-Rituximab Cuts CLL Progression 45%